Adjuvant Tamoxifen Prescription in Women 65 Years and Older With Primary Breast Cancer
The DOI matches its Crossref record.
Abstract
PURPOSE: We examined patterns of adjuvant tamoxifen discussion and prescription among breast cancer patients age 65 years and older. METHODS: We selected from women diagnosed with primary breast cancer those with (1) stage I (tumor diameter ≥ 1 cm), stage II, or stage IIIa disease; (2) age 65 years or older on the date of diagnosis; and (3) permission from the attending physician to contact. Data were collected from consenting patients’ medical records, telephone interviews with patients, and mailed questionnaires completed by their physicians. RESULTS: We obtained medical record and interview data for 698 patients. The oldest patients (odds ratio [OR], 0.45; 95% confidence interval [CI], 0.23 to 0.87 for those aged 80+ relative to those aged 65 to 69 years old), those with more comorbid conditions (each additional comorbid condition reduced the odds of discussion by 0.84; 95% CI, 0.73 to 0.96), and those who were estrogen receptor–negative (OR, 0.56; 95% CI, 0.32 to 0.99) were less likely to report discussion of tamoxifen therapy with a physician. Older patients (OR, 2.17; 95% CI, 1.18 to 4.01 for 70- to 79-year-olds relative to 65- to 69-year-olds; OR, 2.44; 95% CI, 1.11 to 5.34 for those aged 80+ relative to those aged 65 to 69 years old), those who reported a greater influence of information about tamoxifen on decision-making (an increase in 1 SD increased the odds by 7.43; 95% CI, 4.36 to 12.65), and those whose physicians believed that the benefits of tamoxifen outweighed its risks (an increase in 1 SD increased the odds by 1.87; 95% CI, 1.34 to 2.62) were more likely to be prescribed tamoxifen. CONCLUSION: These findings highlight the key role of communication in the care of older women with breast cancer and its ultimate influence on the receipt of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hershman, D. L., Kushi, L. H., Shao, T., Buono, D., Kershenbaum, A., Tsai, W.-Y., Fehrenbacher, L., Lin Gomez, S., Miles, S., & Neugut, A. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9655 · Cited by 828
Moser, A., Stuck, A. E., Silliman, R. A., Ganz, P. A., & Clough-Gorr, K. M. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.04.007 · Cited by 475
Self-citationBreast Cancer Among the Oldest Old: Tumor Characteristics, Treatment Choices, and Survival
Schonberg, M. A., Marcantonio, E. R., Li, D., Silliman, R. A., Ngo, L., & McCarthy, E. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9796 · Cited by 422
Self-citationAdherence to tamoxifen over the five-year course
Lash, T. L., Fox, M. P., Westrup, J. L., Fink, A. K., & Silliman, R. A. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9193-0 · Cited by 320
Self-citationOlder Female Cancer Patients: Importance, Causes, and Consequences of Undertreatment
Bouchardy, C., Rapiti, E., Blagojevic, S., Vlastos, A.-T., & Vlastos, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4208 · Cited by 306
Metadata
- Authors
- Silliman, R. A., Guadagnoli, E., Rakowski, W., Landrum, M. B., Lash, T. L., Wolf, R., Fink, A., Ganz, P. A., Gurwitz, J., Borbas, C., & Mor, V.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-06-01
- Volume
- 20
- Issue
- 11
- Pages
- 2680-2688
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2140016894
- Cited by
- 92
- References
- 0
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjuvant Tamoxifen Prescription in Women 65 Years and Older With Primary Breast Cancer. https://app.cochat.ai/papers/10.1200/jco.2002.08.137
- The paper
- Silliman, R. A., Guadagnoli, E., Rakowski, W., Landrum, M. B., Lash, T. L., Wolf, R., Fink, A., Ganz, P. A., Gurwitz, J., Borbas, C., & Mor, V. (2002). Adjuvant Tamoxifen Prescription in Women 65 Years and Older With Primary Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2002.08.137
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.